Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?

May 01 2012

• By Michael McCaughan

Related Content

Just a Minute: The Final Step in Advisory Committee Process

Mar 01 2011

FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately

Apr 15 2009

Patient Advocacy 3.0: Outreach Stretches to First Stages of Regulatory Development

Apr 16 2012

Weighty Issues: GW Obesity Drug Outcomes Project Tests a Model for Patient Input in Drug Development

May 01 2012

CV Risk Assessment For All Obesity Drugs Seems Inevitable Pre-Approval Requirement

Mar 30 2012

Regulatory Innovation: A Dialogue (Part II)

Mar 15 2012

Weighing the Regulatory Climate: Qnexa and the New Approval Model

Sep 01 2010

A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them

Nov 01 2010

Related Companies

GSK plc

Arena Pharmaceuticals, Inc.

Abbott

AstraZeneca PLC

Novo Nordisk A/S

Sanofi

Additional Topics

Safety Drug Approval Standards Advisory Committees BioPharmaceutical

More from Drug Safety

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window